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Abstract 
Objective: To describe anesthesia for renal transplantation that progressed to a sharp potassium 
increase after kidney reperfusion with Euro-Collins’ solution in the operative ﬁ eld. We will also 
report on diagnosis and treatment used. 
Conclusion: The use of infusion solutions in the surgical ﬁ eld requires careful monitoring, such 
as electrocardiography, measurement of serum potassium, and availability of calcium gluconate, 
insulin, and albuterol for immediate use. The replacement of Euro-Collins’ solution for saline 
solution immediately before the implant may be a useful option in patients with high levels of 
potassium.
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Introduction
Hyperkalemia in anesthesia for renal transplantation used to 
be a more common complication.1 Succinylcholine adminis-
tration for tracheal intubation2,3 and poor dialysis patients4 
and/or insulin-dependent diabetic patients5 have been res-
ponsible for serious anesthetic accidents. Preoperative care 
and stricter use of nondepolarizing muscle relaxants during 
general anesthesia induction have signiﬁ cantly reduced this 
complication. However, there are few recommendations 
regarding risks of hyperkalemia resulting from the use of 
infusion solutions in organ transplantation.6,7 The most 
commonly used solutions are Euro-Collins and University of 
Wisconsin (UW),8 which have high concentration of potassium 
in common similar to that of intracellular ﬂ uid.9 There are 
reports of complications such as rapid increase in serum 
potassium7 and heart failure6 immediately after release of 
vascular anastomoses in perfused kidneys with Euro-Collins’ 
solution.
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Case report
Male patient, aged 32 years, who underwent a second kid-
ney transplant from a living-related donor, with a history 
of uneventful general anesthesia for renal transplantation 
nine years ago. The patient was on dialysis for 16 months, 
reported hypertension four years ago, and urinary infection 
three months ago.
On preanesthetic visit, the patient was in good condition 
and had no complaints. He underwent hemodialysis in the 
morning and had an assessed hemoﬁ ltration of 4 kg. On phy-
sical examination, the patient was afebrile, weighing 79 kg 
with a height of 1.71 m, blood pressure was 130/80 mm Hg, 
and heart rate of 70 bpm. Cardiac auscultation showed mild 
systolic murmur at the apex. We also noted the presence of an 
arteriovenous ﬁ stula in the left upper limb (LUL) and a central 
catheter inserted into the right internal jugular vein. The pa-
tient was taking azathioprine, prednisone, and propranolol. 
Preoperative test results were Hb = 9.93 g%; Ht = 29.28%; 
INR = 1.02; R = 1.12; urea = 80 mg%; creatinine = 5.75 mg%; 
Na + = 134 mEq.L-1; K + = 5.10 mEq.L-1. Electrocardiogram 
(ECG) showed left ventricular overload and chest X-ray an 
increased heart area by left ventricular overload. Patient 
status was considered ASA 3. Midazolam intramuscular (7.5 
mg) was prescribed as pre-anesthetic medication 30 minutes 
before surgery, and general anesthesia was the anesthetic 
technique indicated. 
Anesthesia induction was performed with fentanyl (0.5 
mg), etomidate (16 mg), and cisatracurium (12 mg) and main-
tained with isoﬂ urane vaporized in a 50% mixture of nitrous 
oxide and oxygen. We administered fractionated doses of 
fentanyl and cisatracurium when necessary.
Approximately 1 hour and 45 minutes after the beginning 
of surgery, implantation in the receiver started with anasto-
mosis of donor renal artery to hypogastric artery of receptor 
and renal vein of donor to hypogastric vein of receptor. 
Total duration of vascular anastomosis was 30 minutes. After 
observing the transplanted organ for 5 minutes, we found 
the kidney to be pale, ischemic, and presenting no signs of 
tissue perfusion. The procedure was then re-clamping the 
hypogastric artery and external iliac vein; the arterial anas-
tomosis was undone and an incision was made in the renal 
vein near the anastomosis. Immediately after this procedure, 
we initiated graft reperfusion with Euro-Collins’ solution 
in the surgical ﬁ eld. This procedure lasted 15 minutes. We 
initiated arterial anastomosis and renal vein suture after 
vessel patency.
We diagnosed hyperkalemia shortly after the vascular 
sutures, identiﬁ ed by a change in T-wave morphology that was 
high, symmetrical, and peaked. Arterial blood gas conﬁ rmed 
our clinical suspicion (Table 1).
We immediately initiated rapid administration of polari-
zed solution (1 U of insulin per 5 g of glucose). At this time, 
we also noted the onset of diuresis enhanced by the admi-
nistration of furosemide (60 mg). The results of subsequent 
tests to control serum potassium are shown in Table 2.
During the entire procedure, systolic blood pressure ran-
ged from 130 to 170 mm Hg, heart rate 45 to 80 bpm, central 
venous pressure 5 to 19 cm of water, and pulse oximetry 97% 
to 99%. We maintained hydration with 0.9% saline (3.5 L) 
and furosemide (60 mg), and diuresis at the end of surgery 
Table 1 Arterial Gasometry and other complimentary 
results.
pH  =  7.21 mm Hg Na⁺ = 125 mmol.L-1
pO₂  =  152 mm Hg K⁺ = 8.5 mmol.L-1
pCO₂  =  58.1 mm Hg Ca⁺⁺ = 1.38 mmol.L-1
HCO₃ˉ = 22.6 mmol.L-1 Clˉ = 101 mmol.L-1
tCO₂  =  24.4 mmol.L-1 Glicemia = 134 mg%
BE  =  -5.1 mmol.L-1 Hb = 11.3 gr%
SO₂ = 99.4% Ht  =  35%
Table 2 Results of Subsequent Tests to Control Serum 
Potassium.
Time (hour:minutes) 11:50 12:53 15:00 16:37
Na೛mmol.L-1 125 125 126 128 
K೛ mmol.L-1 8.2 6.9 6.2 5.4
Ca೛೛mmol.L-1 1.32 1.27 1.27 1.22
Clˉ mmol.L-1 101 102 102 102
Glicemia mg% 136 155 155 73
Hb g% 11.1 10.9 11.1 10.3
Ht % 34.2 33.8 34.2 31.8
Table 3 Euro-Collins’ Solution Characteristics.
Potassium 115 mmol.L-1
Sodium 10 mmol.L-1
Phosphate 100 mmol.L-1
Chloride 15 mmol.L-1
Bicarbonate 10 mmol.L-1
Dextrose 198 mmol.L-1
Osmolarity 406 mOsm.L-1
was 1.5 L. We reversed neuromuscular block with standard 
doses of atropine and prostigmine, followed with tracheal 
extubation. The entire procedure lasted 5 hours. 
Discussion
The strategies used for organ preservation aim to reduce the 
adverse cellular effects following ischemia and reperfusion. 
Simply cooling the kidney surface does not allow an adequate 
preservation for longer periods. Kidney perfusion with appro-
priate electrolyte solutions is one of the strategies used for 
organ preservation because it allows cold ischemic periods 
exceeding 24 hours. It is the time often required for organ 
transportation, histocompatibility testing, and transplant 
recipient preparation in case of deceased donor 9. One of the 
ﬁ rst solutions used for preservation is Euro-Collins, whose 
characteristics are shown in Table 3.6
Other more recent solutions, such as the University of 
Wisconsin (UW), represent a breakthrough because they 
protect organs very susceptible to ischemia, such as liver 
and pancreas for longer periods. It is the most used perfusion 
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solution in organ transplantation but, similar to the Euro-
Collins’ solution, it has high potassium concentrations like 
the intracellular ﬂ uid.6
Since the introduction of infusion ﬂ uids, few cases repor-
ted the association of these solutions with complications such 
as hyperkalemia. Severe cases of increased serum potassium 
progressing to sudden cardiac arrest have been reported with 
Euro-Collins’ solution, seconds after the release of vascular 
anastomoses.7,8 In a subsequent study, Hirshman noted that 
immediately after the release of vascular anastomoses, 
the levels of potassium in blood samples taken from the 
right atrium could present values abnormally high and that 
a slow and gradual release of vascular clamps attenuated 
this effect.10 
Studies showing serum potassium variations caused by 
perfusion ﬂ uid passing through the systemic circulation found 
no signiﬁ cant changes. However, there are recommendations 
for some special situations, such as transplantation of adult 
kidneys into very small children and renal transplant in 
which anastomosis is done with the receptor’s artery and 
aorta and remains clamped throughout the period of vascular 
sutures.10 
Euro-Collins’ solution has been routinely used in our 
service for renal perfusion in transplantation in adults and 
children from living relatives and deceased donors. It is also 
used in the actual surgical ﬁ eld in situations where there is 
no adequate renal perfusion requiring vascular anastomosis 
remake.
We suggest three possible explanations for this 
complication:
1.  Intravascular administration of Euro-Collins’ solution 
(600 mL) with high concentrations of potassium, re-
sulting from double renal perfusion;
2.  Intravascular absorption of Euro-Collins’ solution 
by the bloody areas exposed during surgery due to 
inadequate suction of irrigation ﬂ uid; 
3.  Accidental instillation of ﬂ uid infusion near the renal 
vein opening.
Although it is not usual we have performed renal reper-
fusion in the surgical ﬁ eld with Euro-Collins’ solution  in 
other opportunities during our service. We have never seen 
a similar complication requiring special care. 
In this particular patient, we believe that all three 
factors, in addition to serum potassium concentration over 
the upper limit of the normal range, were the cause of this 
complication.
However, it is worth remembering that there are other 
causes of hyperkalemia during anesthesia for renal trans-
plantation which can overlap with the perfusion solution, 
such as potassium release induced by succinylcholine 
administration2,3 and rapid blood transfusion.11
Potassium concentration above 7.5 mEq.L-1 is considered 
a severe hyperkalemia12 which may progress to heart rhythm 
disorder and be life-threatening.13 However, in many patients 
it is asymptomatic and perceived only in laboratory tests. 
Although there are studies showing that approximately half 
of patients with serum potassium greater than 6.5 mEq.L-
1present no ECG changes.14 ECG is the ﬁ rst indicator of 
hyperkalemia, showing symmetric and peaked tall T-waves, 
absence of P-wave, QRS enlargement, arrhythmias, and 
cardiac arrest.15
Treatment of severe hyperkalemia should meet three 
basic stages. The ﬁ rst is stabilizing the myocardium - which 
has decreased its susceptibility to cardiac arrhythmias - with 
intravenous administration of 10% calcium gluconate over 3-5 
minutes and ECG monitoring. The effects can be observed 
when the infusion starts, and duration of action is 30 to 60 
minutes. The second stage consists of diverting potassium 
to intracellular space with insulin (10 U in 25 g glucose); β2 
agonists, such as nebulization of salbutamol (10-20 mg in 
4 mL saline and sodium bicarbonate solution), are used if 
the patient is in metabolic acidosis. The administration of 
insulin/glucose decreases plasma potassium levels in 15 to 
30 minutes after the start of infusion, and duration of action 
is 2 hours. Salbutamol is the most widely used β2 agonist for 
hyperkalemia treatment. It is administered by nebulization, 
has a rapid onset of action, and the effects can be noticed 30 
minutes after starting administration. Salbutamol may also 
be administered intravenously at a dose of 0.5 to 2.5 mg. 
The effects of different routes of administration in serum 
potassium are not well deﬁ ned; however, complications such 
as tachycardia, increased blood pressure, and palpitations are 
more common with intravenous administration. Salbutamol 
may be used concomitantly with insulin, whose effects are 
potentiated. The effect of sodium bicarbonate on hiperkale-
mia is less than that of insulin and β2 adrenergic receptors and 
seems to occur only in the presence of metabolic acidosis.16,17 
Thus, the systematic use of sodium bicarbonate to treat 
hyperkalemia is controversial and not recommended.18 The 
third stage is removing potassium from the body, which 
can be achieved with the use of diuretics, cation exchange 
resins, and dialysis that is the most effective treatment for 
serum potassium removal.19 Furosemide acts on the tubular 
lumen of the thick loop of Henle and inhibits sodium and 
potassium cotransport across the apical membrane. It is a 
potent diuretic and, thus, may be used in the treatment of 
hyperkalemia, provided there is some residual function. The 
dose used is 40-80 mg intravenously. Ion exchange resins are 
administered orally or by enemas and remove potassium 
from the extracellular ﬂ uid in exchange for cation, such as 
sodium or calcium, through the intestinal wall. The effect 
can take up to 6 hours to be achieved, hence its limited use 
in emergencies. The deﬁ nitive treatment of hyperkalemia 
is dialysis in its various forms. The most effective is hemo-
dialysis, which can be adapted to quickly remove potassium 
by decreasing its concentration or increasing bicarbonate 
concentration in dialysis ﬂ uid or by increasing the rate of 
blood ﬂ ow in the dialysis machine.20 
In our case, treatment consisted of administration of 
furosemide and polarized solution. Salbutamol was not used 
because it was not available in the operating room. Calcium 
gluconate was not administered because the response to the 
treatment used was immediate and effective, probably by 
early concomitant diuresis. 
Although rare, hyperkalemia associated with the use of 
infusion solutions is a complication that cannot be ignored. 
We therefore recommend that ECG monitoring should be 
done effectively with kidney perfusion with these solutions 
within the surgical ﬁ eld, and a dosage of potassium can be 
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quickly administered for diagnosis. The ready availability of 
calcium gluconate, insulin, and albuterol for immediate use 
is a practice that should be disseminated. Using electrolytic 
solutions, such as saline solution, as a substitute for Euro-
Collins’ solution is a useful option in patients with elevated 
potassium levels.
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